Analysts Expect Paratek Pharmaceuticals, Inc. (PRTK) to Announce -$0.75 EPS
Wall Street brokerages expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) will report ($0.75) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Paratek Pharmaceuticals’ earnings, with estimates ranging from ($0.88) to ($0.66). Paratek Pharmaceuticals posted earnings of ($1.16) per share in the same quarter last year, which would indicate a positive year over year growth rate of 35.3%. The business is scheduled to announce its next earnings results on Thursday, March 1st.
According to Zacks, analysts expect that Paratek Pharmaceuticals will report full year earnings of ($3.39) per share for the current year, with EPS estimates ranging from ($3.95) to ($3.05). For the next financial year, analysts expect that the firm will post earnings of ($3.38) per share, with EPS estimates ranging from ($4.43) to ($2.59). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Paratek Pharmaceuticals.
Several research analysts have weighed in on the company. Cantor Fitzgerald set a $50.00 price objective on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, July 17th. HC Wainwright upped their price target on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, July 18th. BidaskClub cut Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Saturday, August 5th. Finally, Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and set a $36.00 price target on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $40.00.
Institutional investors have recently made changes to their positions in the company. Great West Life Assurance Co. Can bought a new position in shares of Paratek Pharmaceuticals during the 3rd quarter valued at about $104,000. SG Americas Securities LLC bought a new position in shares of Paratek Pharmaceuticals during the 3rd quarter valued at about $123,000. Legal & General Group Plc increased its position in shares of Paratek Pharmaceuticals by 13.3% during the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after purchasing an additional 687 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Paratek Pharmaceuticals during the 2nd quarter valued at about $172,000. Finally, Citigroup Inc. increased its position in shares of Paratek Pharmaceuticals by 19,470.0% during the 2nd quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after purchasing an additional 7,788 shares during the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.
Shares of Paratek Pharmaceuticals (NASDAQ PRTK) opened at $21.65 on Tuesday. Paratek Pharmaceuticals has a 1-year low of $12.55 and a 1-year high of $29.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.